Tapering of SSRI treatment to mitigate withdrawal symptoms
- PMID: 31230676
- PMCID: PMC7613095
- DOI: 10.1016/S2215-0366(19)30183-X
Tapering of SSRI treatment to mitigate withdrawal symptoms
Conflict of interest statement
We declare no competing interests.
Comment in
-
Tapering of SSRI treatment to mitigate withdrawal symptoms - Authors' reply.Lancet Psychiatry. 2019 Jul;6(7):562-563. doi: 10.1016/S2215-0366(19)30219-6. Lancet Psychiatry. 2019. PMID: 31230678 No abstract available.
Comment on
-
Tapering of SSRI treatment to mitigate withdrawal symptoms.Lancet Psychiatry. 2019 Jun;6(6):538-546. doi: 10.1016/S2215-0366(19)30032-X. Epub 2019 Mar 5. Lancet Psychiatry. 2019. PMID: 30850328 Review.
References
-
- Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6:538–46. - PubMed
-
- Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22:40–45. - PubMed
-
- Davies J, Regina P, Montagu L. Antidepressant withdrawal: a survey of patients’ experience by the All Party Parliamentary Group for Prescribed Drug Dependence. 2018. Sep, [accessed April 2, 2019]. http://prescribeddrug.org/wp-content/uploads/2018/10/APPG-PDD-Survey-of-... .
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
